PIK3CA and endometrioid adenocarcinoma: The authors also preclinically tested the PI3K inhibitor AZD8835 in two subrenal xenografts, an endometrial clear cell carcinoma harboring a PTEN deletion and an endometrioid carcinoma harboring a PIK3CA mutation.